<DOC>
	<DOCNO>NCT01436565</DOCNO>
	<brief_summary>Primary Objective : - To determine maximum tolerate dose ( MTD ) recommend Phase 2 dose ( RP2D ) SAR245408 administer combination SAR256212 adult patient locally advance metastatic solid tumor . Secondary Objectives : - To characterize global safety profile SAR245408 combination SAR256212 - To evaluate pharmacokinetic ( PK ) profile SAR245408 SAR256212 use combination - To evaluate objective response rate ( ORR ) tumor volume change ( expansion cohort ) - To determine immunogenicity SAR256212 administer SAR245408</brief_summary>
	<brief_title>A Study Investigational SAR256212 Combination With SAR245408 Patients With Solid Tumor Cancers</brief_title>
	<detailed_description>There 28 day screen period follow 28 day cycle ( 21 day cycle every three week dose regimen , use ) . Patients continue receive SAR245408/SAR256212 long clinical benefit study withdrawal criterion meet . The last posttreatment visit 60 day last dose IMP-related toxicity resolve deem irreversible , whichever later .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Metastatic locally advance nonhematological cancer , alternative therapy available Written inform consent For dose expansion : Patient 's tumor harbor activate mutation phosphoinositide3kinase , catalytic , alpha polypeptide ( PIK3CA ) Tissue archive sample Measurable evaluable disease Exclusion criterion : Patient le 18 year old ECOG ( Eastern Cooperative Oncology Group ) performance status &gt; 2 Any serious active disease comorbid condition , , opinion Investigator , could interfere safety patient ability patient comply study , interpretation result Poor bone marrow reserve define absolute neutrophil count &lt; 1.5 x 109/L platelet &lt; 100 x 109/L Poor organ function define 1 following : Total bilirubin &gt; 1.5 x ULN ( upper limit normal ) AST ( aspartate aminotransferase ) and/or ALT ( alanine aminotransferase ) &gt; 2.5 x ULN Serum creatinine &gt; 1.5 x ULN and/or creatinine clearance &lt; 60 mL/min PT/ ( INR ) ( prothrombin time ) ( International Normalized Ratio ) and/or partial thromboplastin time ( PTT ) test result ≥1.3 ULN Pregnant breastfeed woman No use effective birth control method , applicable No resolution specific toxicity ( exclude alopecia ) relate prior anticancer therapy Grade ≤1 accord NCI common terminology criterion adverse event ( CTCAE ) v.4.0 Any follow within 6 month prior enrollment : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft surgery , clinically symptomatic uncontrolled cardiovascular disease , clinically significant cardiac arrhythmia ( Grade 3/4 ) Baseline correct QT interval ( QTc ) &gt; 460 ms. NYHA Class III ( New York Heart Association ) IV congestive heart failure LVEF ( leave ventricular ejection fraction ) &lt; low limit normal ( LLN ) institution Uncontrolled intercurrent illness include , limited , ongoing active infection ( include cytomegalovirus , EpsteinBarr virus , toxoplasmosis , hepatitis B C , positive human immunodeficiency virus ( HIV ) , hypertension , uncontrolled diabetes . Previous treatment selective PI3K inhibitor ( phosphoinositide3kinase , catalytic , alpha polypeptide ) , mTOR ( mechanistic target rapamycin ) inhibitor , AKT inhibitor ( vakt murine thymoma viral oncogene homolog 1 ) Known hypersensitivity investigational medicinal product ( ) excipients , patient hypersensitivity reaction fully human monoclonal antibody Cytotoxic chemotherapy ( include investigational cytotoxic agent ) biologic agent ( antibody , immune modulators , cytokine ) within 4 week , nitrosoureas mitomycin C within 6 week , first dose study treatment Prior radiation therapy within 2 week first dose study treatment Prior major surgery patient recover stabilize Any investigational therapy within 4 week prior first dose study treatment Brain tumor brain metastasis consider eligible patient receive radiation therapy brain metastasis within 2 week enrollment stable dose steroid 2 week Ongoing anticoagulation therapeutic dos warfarin ( lowdose warfarin ≤1 mg/day permit ) . HBA1C ( hemoglobin A1c ) &gt; 7 patient require medication glycemic control The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>